Clinical Trial Details


Back to Clinical Trials Database

Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy.

Study documentation

Trial Status Recruiting
Dates Date of activation: 12-Apr-2018
Data management at EORTC Yes
Design Phase 2
Not randomized / N.A.
Targeted Sample size EORTC Groups: 55 - All Groups: 55
Treatment Drug
Ipilimumab, Nivolumab
Study Staff Nicolas Girard (Study Coordinator) , Institut Curie- Hopital de Paris, PARIS CEDEX 05
Christine Bastin (Pharmacovigilance Manager) , EORTC Headquarters, Brussels
Marion Bettega (Clinical Operations Assistant) , EORTC Headquarters, Brussels
Emanuel Buhrer (Medical Fellow) , EORTC Headquarters, Brussels
Alessandro Fadel (Clinical Operations Assistant) , EORTC Headquarters, Brussels
Beatrice Fournier (Clinical Scientist) , EORTC Headquarters, Brussels
Selin Gundogan (Junior Clinical Operations Manager) , EORTC Headquarters, Brussels
Hafida Lmalem (Imaging Officer) , EORTC Headquarters, Brussels
Belma Malanda (Project Manager) , EORTC Headquarters, Brussels
Marie Morfouace (TR Scientist) , EORTC Headquarters, Brussels
Ana Oliveira (Data Manager) , EORTC Headquarters, Brussels
Solange Peters (Study Co-Coordinator) , Centre Hospitalier Universitaire Vaudois - Lausanne, Lausanne
Yassin Pretzenbacher (Statistician) , EORTC Headquarters, Brussels
Miguel Remis (Clinical Research Associate/Monitor) , EORTC Headquarters, Brussels
Jelle Stans (Regulatory Affairs Administrator) , EORTC Headquarters, Brussels
Egle Venslovaite (Regulatory Affairs Administrator) , EORTC Headquarters, Brussels
Eleni Xenophontos (Clinical Research Physician) , EORTC Headquarters, Brussels
Christine de Balincourt (Lead CRA) , EORTC Headquarters, Brussels
Gaetan de Schaetzen (Clinical Operations Manager) , EORTC Headquarters, Brussels
Type of cancer Thymoma
Participating groups EORTC Lung Cancer Group
European Thoracic Oncology Platform
Recruiting centers Academisch Ziekenhuis Maastricht (Maastricht, Netherlands)
CHU de Brest (Brest, France)
CHU de Grenoble - La Tronche - Hopital A. Michallon (GRENOBLE CEDEX 9, France)
CHU de Lyon - Hopital Louis Pradel (BRON, France)
CHU de Toulouse - Hopital Larrey (TOULOUSE CEDEX 9, France)
Centre Francois Baclesse (CLCC) (CAEN CEDEX 5, France)
Centre Hospitalier Universitaire Vaudois - Lausanne (Lausanne, Switzerland)
Erasmus MC (Rotterdam, Netherlands)
Gustave Roussy (VILLEJUIF CEDEX, France)
HM Delfos Hospital-CIOCC (Barcelona, Spain)
Hopital Nord (APHM) (Marseille, France)
Hospital Universitari Vall d’Hebron -Vall d'Hebron Institut Oncologia (Barcelona, Spain)
Hospital Universitario 12 De Octubre (Madrid, Spain)
Institut Curie- Hopital de Paris (PARIS CEDEX 05, France)
Institut Jules Bordet (Anderlecht, Belgium)
Institut de Cancerologie de Lorraine (VANDOEUVRE LES NANCY CEDEX, France)
NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital (Glasgow, United Kingdom)
Royal Marsden Hospital - Chelsea, London (London, United Kingdom)
Royal Marsden Hospital - Sutton, Surrey (Surrey, United Kingdom)
The Christie NHS Foundation Trust (Manchester, United Kingdom)
The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis (Amsterdam, Netherlands)
UniversitaetsSpital Zurich (Zurich, Switzerland)
Universitair Ziekenhuis Antwerpen (Edegem, Belgium)
Centers to be activated Institut du Cancer de Montpellier (MONTPELLIER CEDEX 5, France)
Protocol summary
NCT number NCT03134118
EudraCT 2015-005504-28
Financial Support Educational Grant